Drug intelligence / Profile preview

BI 765080

Development stage: Phase 1
Lead developer: Boehringer
Modality: Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

BI 765080 is an investigational antibody drug developed by Boehringer Ingelheim. It acts as a SIRPα (signal regulatory protein alpha) inhibitor, representing a novel mechanism of action. The drug is being evaluated for its pharmacokinetics, safety, tolerability, and bioavailability in healthy volunteers. As of now, it has not been approved for any indication and remains in early clinical development[2][4]. Its primary mechanism involves blocking the SIRPα pathway, which may have applications in immunotherapy by modulating immune cell activity.

Targets

SIRPA (Signal-regulatory protein alpha)

Beyond the preview

Go deeper on BI 765080.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 765080.

Explore the full profile